P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system

Pepijn W. A. Thomas(Radboud University Nijmegen), Frank Hoentjen(Radboud University Nijmegen), Naomi T. Jessurun(Netherlands Pharmacovigilance Centre Lareb), Robert West(The Behaviouralist (United Kingdom)), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), M. Russel(Medisch Spectrum Twente), Jeroen M. Jansen(OLVG), J. Van Lint(Netherlands Pharmacovigilance Centre Lareb)
Journal of Crohn s and Colitis
January 1, 2020
10.1093/ecco-jcc/jjz203.459
Cited by 3

Related Papers

Cassini Observes the Active South Pole of Enceladus
|Science|2006|1.2k
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
|The Lancet|2016|1.2k
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis
|New England Journal of Medicine|2021|269
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252